Search Results
Results found for "Han Zhou"
- What's Going On with GPCRs?! Find Out in This Week's Update! ⦿ Nov 4 - 10, 2024
GPCR-BSD: a database of binding sites of human G-protein coupled receptors under diverse states Fan Liu , Han Zhou , Xiaonong Li , Liangliang Zhou , Chungong Yu , Haicang Zhang , Dongbo Bu 🤩 Seriously, why would
- A robust and Efficient FRET-Based Assay for Cannabinoid Receptor Ligands Discovery.
.; Han, G. W.; Wu, Y.; Zhao, S.; Shui, W.; Li, S.; Korde, A.; Laprairie, R. B.; Stahl, E. L.; Ho, J. -H.; Zvonok, N.; Zhou, H.; Kufareva, I.; Wu, B.; Zhao, Q.; Hanson, M. A.; Bohn, L. -H.; Wu, Y.; Wu, L.; Popov, P.; Benchama, O.; Zvonok, N.; Locke, K.; Qu, L.; Han, G. W.; Iyer, M.
- Structural landscape of the Chemokine Receptor system
6P4]CCL5), a chemokine antagonist ([5P7]CCL5), and a small-molecule inverse agonist (maraviroc) (Tan, Zhu et al. 2013, Zheng, Han et al. 2017, Isaikina, Tsai et al. 2021, Zhang, Chen et al. 2021). its constitutive activity (Yen, Schafer et al. 2022) which is also supported by mutagenesis studies (Han
- GPCRs are not simple on-off switches: deep dive into GPCR-ligand interactions
disruption of natural spatial and temporal signaling patterns regulated by physiological systems (Wold and Zhou intervention for metabolic diseases such as liver disease, obesity and diabetes (Secor et al. 2021; Wold and Zhou
- 📰 GPCR Weekly News, July 1 to 7, 2024
Jianming Han, Tao Che for their analysis of GPCR-G protein selectivity revealed by structural pharmacology
- The Perils and Guardrails of Modifying Signalling Proteins in Bioassays
Wager TT, Hou X, Verhoest PR, Villalobos A. Sun D, Gao W, Hu H, Zhou S. Why 90% of clinical drug development fails and how to improve it? González-Maeso J, Weisstaub NV, Zhou M, Chan P, Ivic L, Ang R, et al.
- Illuminating GPCR Research: FRET and BRET-Based Sensors Shed Light on Cellular Signaling
Zhou, Y., et al., Multiple GPCR Functional Assays Based on Resonance Energy Transfer Sensors.
- Targeting Intracellular Allosteric Sites in GPCRs
therapeutic intervention for metabolic diseases such as liver disease, obesity and diabetes (Wold and Zhou
- ⛵Sailing the GPCR Seas: Your Weekly Research Voyage! ⦿ Nov 11 - 17, 2024
Week’s Highlights: SNX9 family mediates βarrestin-independent GPCR endocytosis Valeria Robleto , Ya Zhuo
- Chemokine receptor-targeted drug discovery: progress and challenges
immunosuppressive tumor microenvironment, and facilitate metastatic spread (Nagarsheth, Wicha, and Zou
- Overview of adhesion GPCRs self-activation
Qian, Y., Ma, Z., Liu, C., Li, X., Zhu, X., Wang, N., Xu, Z., Xia, R., Liang, J., Duan, Y., Yin, H.,
